Control of Hypertension In Pregnancy Study randomised controlled trial-are the results dependent on the choice of labetalol or methyldopa?
| Autor: | Amiram Gafni, Gideon Koren, Elizabeth Asztalos, Jim G Thornton, J.-M. Moutquin, J. W. Ganzevoort, Laura A. Magee, J. Menzies, R. Welch, S. Ross, Tang Lee, E. Rey, Joel Singer, Kellie E. Murphy, P. von Dadelszen, Michael Helewa, A. Gruslin, Alexander G. Logan, Shoo K. Lee, Eileen K. Hutton, J. Johanna Sanchez |
|---|---|
| Přispěvatelé: | ARD - Amsterdam Reproduction and Development, Obstetrics and Gynaecology |
| Rok vydání: | 2015 |
| Předmět: |
Gestational hypertension
Adult medicine.medical_specialty Hypertension in Pregnancy Population Clinical Decision-Making Pregnancy Complications Cardiovascular Blood Pressure 030204 cardiovascular system & hematology law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Pre-Eclampsia law Pregnancy Risk Factors Internal medicine medicine Maternal hypertension Humans Labetalol Methyldopa cardiovascular diseases education Antihypertensive Agents education.field_of_study 030219 obstetrics & reproductive medicine business.industry Obstetrics and Gynecology Prenatal Care Hypertension Pregnancy-Induced Infant Low Birth Weight medicine.disease 3. Good health Surgery Blood pressure Treatment Outcome Hypertension Premature Birth Female business medicine.drug |
| Zdroj: | BJOG, 123(7), 1135-1141. Wiley-Blackwell |
| ISSN: | 1471-0528 1470-0328 |
| Popis: | Objective To determine whether the difference in outcomes between ‘less tight’ (target diastolic blood pressure [dBP] of 100 mmHg) versus ‘tight’ control (target dBP of 85 mmHg) in the CHIPS Trial (ISRCTN 71416914, http://pre-empt.cfri.ca/;CHIPS) depended on the choice of labetalol or methyldopa, the two most commonly used antihypertensive agents in CHIPS. Design Secondary analysis of CHIPS Trial data. Setting International multicentre randomised controlled trial (94 sites, 15 countries). Population or sample A total of 987 women with non-severe non-proteinuric pregnancy hypertension. Methods Logistic regression was used for comparisons of ‘less tight’ versus ‘tight’ control among women treated with labetalol (but not methydopa) versus methyldopa (but not labetalol). Analyses were adjusted for the influence of baseline factors, including use of any antihypertensive therapy at randomisation. Main outcome measures Main CHIPS Trial outcomes: primary (perinatal loss or high-level neonatal care for > 48 hours), secondary (serious maternal complications), birthweight |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text